STOCK TITAN

Amicus Therapeutics, Inc - FOLD STOCK NEWS

Welcome to our dedicated news page for Amicus Therapeutics (Ticker: FOLD), a resource for investors and traders seeking the latest updates and insights on Amicus Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Amicus Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Amicus Therapeutics's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.65%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.3%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.6%
Tags
none
Amicus Therapeutics, Inc

Nasdaq:FOLD

FOLD Rankings

FOLD Stock Data

3.09B
222.12M
0.75%
109.94%
11%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
PHILADELPHIA

About FOLD

amicus therapeutics is a global, patient-centric biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. we have a unique set of platform technologies and medicines in development for patients living with the lysosomal storage disorders fabry disease and pompe disease and we are committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for these and other rare diseases. the needs of patients in the rare disease community are at the center of our inventive science, our commercial organization, and our clinical programs. our goal throughout all levels of the organization is to make a meaningful difference in the lives of these patients and their caregivers. several opportunities are available to join our team as we build a leading global biotechnology company focused on rare metabolic diseases. our amicus footprint spans 27 countries including our g